Case series of light chain systemic amyloidosis in a high complexity hospital in Medellín
Serie de casos de amiloidosis sistémica de cadenas ligeras en un hospital de alta complejidad en Medellín
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Show authors biography
Amyloidosis is a group of rare diseases characterized by the abnormal deposit of proteins in the tissues. It can affect any organ except the central nervous system and have a heterogeneous clinical presentation depending on the damage to the involved organ. Methods: We present a descriptive, retrospective case series study of 11 patients with a confirmed diagnosis of light chain amyloidosis in a highly complexity institution in Medellín. The objective was to describe the clinical, paraclinical, and imaging presentation of patients, during a period between 2014 and 2020. A collection of demographic and clinical data from medical records was carried out, to later compare them with data from the literature. Results: A total of 11 patients were found, in which cardiac and renal involvement were the most common. The main symptoms reported were edema in the extremities, asthenia, adynamia, weight loss and dyspnea. The organs where the amyloid deposit was identified by histopathology were bone marrow, gastrointestinal tract, kidney, lung and skin. In the electrocardiogram the two main findings were a pattern of low voltage and pseudoinfarction. Left ventricular hypertrophy and pericardial effusion were common echocardiographic findings. Conclusion: the most frequent type of monoclonal gammopathy in the series was due to lambda light chains.
Article visits 210 | PDF visits 162
- Fontana M, Ćorović A, Scully P, Moon JC. Myocardial Amyloidosis: The Exemplar Interstitial Disease [Internet]. JACC. Cardiovascular imaging. 2019. Disponible en: https://doi.org/10.1016/j.jcmg.2019.06.023
- Manolis AS, Manolis AA, Manolis TA, Melita H. Cardiac amyloidosis: An underdiagnosed/underappreciated disease [Internet]. European Journal of Internal Medicine. 2019;67:1–13. Disponible en: https://doi.org/10.1016/j.ejim.2019.07.022
- Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020 [Internet]. Blood. 2020136(23):2620–7. Disponible en: https://doi.org/10.1182/blood.2020006913
- Gertz MA. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment [Internet]. American Journal of Hematology. 2022;97(6):818–29. Disponible en: https://doi.org/10.1002/ajh.26569
- Al Hamed R, Bazarbachi AH, Bazarbachi A, Malard F, Harousseau JL, Mohty M. Comprehensive Review of AL amyloidosis: some practical recommendations [Internet]. Blood Cancer Journal. 2021;11(5):97. Disponible en: https://doi.org/10.1038/s41408-021-00486-4
- Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes [Internet]. Journal of Clinical Oncology. Wolters Kluwer; 2012; 30(36):4541–9.Disponible en: https://doi.org/10.1200/JCO.2011.37.7614
- Lacouture-Fierro JA, Mejía-Buriticá L, Ribero-Vargas DA. Amiloidosis AL: conceptos actuales [Internet]. Medicina y Laboratorio. 2022;26(2):119–39. Disponible en: https://doi.org/10.36384/01232576.572
- Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis [Internet]. The Lancet. Elsevier; 2016;387(10038):2641–54. Disponible en: https://doi.org/10.1016/S0140-6736(15)01274-X
- Villalba L, Daquarti G, Corneli M. Imágenes en amiloidosis cardiaca [Internet]. Disponible en: https://doi.org/10.32407/rcon/2020154/0090-0097
- Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association [Internet]. Circulation. 2020;142(1). Disponible en: https://doi.org/10.1161/CIR.0000000000000792
- Systemic immunoglobulin light chain amyloidosis. Nature Reviews Disease Primers [Internet]. Disponible en: https://doi.org/10.1038/s41572-018-0040-5
- Ozga M, Zhao Q, Benson Jr. D, Elder P, Williams N, Bumma N, et al. AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival [Internet]. Cancer Medicine. 2021;10(3):965–73. Disponible en: https://doi.org/10.1002/cam4.3683
- Cornell RF, Fraser R, Costa L, Goodman S, Estrada-Merly N, Lee C, et al. Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden [Internet]. Transplantation and Cellular Therapy. 2021;27(3):264.e1-264.e7. Disponible en: https://doi.org/10.1016/j.jtct.2020.11.018
- Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, et al. A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and Colchicine. N Engl J Med. 1997;336(17):1202–7.
- Kastritis E, Leleu X, Arnulf B, Zamagni E, Cibeira MT, Kwok F, et al. Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis [Internet]. Journal of Clinical Oncology. 2020;38(28):3252–60. Disponible en: https://doi.org/10.1200/JCO.20.01285
- Venner CP, Lane T, Foard D, Rannigan L, Gibbs SDJ, Pinney JH, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival [Internet]. Blood. 2012;119(19):4387–90. Disponible en: https://doi.org/10.1182/blood-2011-10-388462
- Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis [Internet]. Blood. 2012;119(19):4391–4. Disponible en: https://doi.org/10.1182/blood-2011-11-390930
- Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis [Internet]. New England Journal of Medicine. 2021;385(1):46–58. Disponible en: http://www.nejm.org/doi/10.1056/NEJMoa2028631
- Palladini G. Advances in the treatment of light chain amyloidosis: Current Opinion in Oncology [Internet]. LWW. Disponible en: https://doi.org/10.1097/CCO.0000000000000881
- Staron A, Zheng L, Doros G, Connors LH, Mendelson LM, Joshi T, et al. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study [Internet]. Blood Cancer Journal. Nature Publishing Group; 2021;11(8):1–10. Disponible en: https://doi.org/10.1038/s41408-021-00529-w
Information
